SOLICITATION NOTICE
R -- Molecular Biology Professional Services
- Notice Date
- 12/9/2014
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NIH-NHLBI-CSB-DE-2015-039-KEW
- Archive Date
- 1/1/2015
- Point of Contact
- Kyle Wisor, Phone: 3014023670, Rashida Ferebee,
- E-Mail Address
-
Kyle.Wisor@nih.gov,
(Kyle.Wisor@nih.gov, ontracting)
- Small Business Set-Aside
- N/A
- Description
- (1) Action Code: Combined Synopsis/Solicitation (2) Date: December 9th (3) Year: 2014 (4) Contracting Office Zip Code: 20892 (5) Classification Code: R499 (6) Contracting Office Address: 6701 Rockledge Drive Rockledge II Bethesda, MD 20892 (7) Subject/Title: Molecular Biology Professional Services (8) Proposed Solicitation Number: HHS-NIH-NHLBI-CSB-DE-2015-039-KEW (9) Closing Response Date: December 17th, 2014 (10) Contact Point: Kyle Wisor, Contract Specialist (11) Contract Award and Solicitation Number: TBD (12) Contract Award Dollar Amount: UKN (13) Contract Line Item Number(s): TBD (14) Contractor Award Date: TBD (15) Contractor Name: TBD (16) Description: Molecular Biological Services (i) "This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued." (ii) The solicitation number is HHS-NIH-NHLBI-CSB-DE-2015-019-KEW and the solicitation is issued as an request for quote (RFQ). (iii) The solicitation document, the incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-78 effective 25 NOV 2014. (iv) There are no set-aside restrictions. The associated NAICS code is 541712, Biology research and development laboratories or services, and the small business size standard is 500 employees. The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13. (v) The Contractor Requirements are listed below: (vi) The Contractor Shall: 1. Statement of Work In this study, the objective is to identify any salivary gland abnormalities that may predispose to Salivary Gland dysfunction in Sjogren's Syndrome patients, to explore if the striking female predominance of SS can be explained by intrinsic differences in salivary glands, to identify initiators of disease, and compare the gene expression profiles of healthy men and women as well as mouse models of the disease. This approach may identify abnormalities that are either intrinsic to the salivary gland (male to female and normal to SS comparison) or are important in the chronic inflammatory process (viral infection). These studies are covered under protocols 84-D-0056, 94-D-0018 and 99-D-0070. Task 1: Prepare and analyze cells and tissue from Sjogren's patients and controls Task 2: Hybridize isolated RNA on microarrays Task 3: Normalize signal from arrays and extract data on differentially expressed transcripts using multiple bioinformatics software packages. Task 4: Rank order differentially expressed transcripts based on statistical probability analysis, validate candidate differentially expressed transcripts by PCR, immuno, or hybridization techniques. Task 5: Develop and test animal models to validate phenotypic effect of differentially expressed transcripts. Task 6: Develop models to test induction of differential expression of transcripts. Task 7: Isolate and characterize particles associated with viral transcripts. Task 8: The contractor maybe asked to attend specific conferences to present findings from this study. Completion of tasks 1-4 will be done sequentially and are estimated to take 10-12 weeks to complete. Task 5-7 maybe initiated simultaneously upon completion of tasks 1-4 and are estimated to take 12-24 weeks to complete. 2. Deliverables: All research data, including results obtained through the microarray process, as well as other relevant patient data, will be collected and maintained on a daily basis in the lab on-site in Building 10. The contractor will meet weekly with the project officer and present a summary report of the project. The contractor will prepare an overview report bimonthly presented to the project officer and selected scientists. The contractor will organize and provide the raw data for each experiment conducted and prepare a summary figure with legend for each experiment initiated. The contractor will prepare a final draft report for the period in the form of a manuscript(s) ready for submission to a peer reviewed journal(s). The completed final summary must be submitted before the end of the contract period to the Project Officer. Deliverable 1: On a daily basis, all research data will be collected, maintained, and delivered to the Project Officer via email. Deliverable 2: A weekly summary report of the project will be presented to the Project Officer in person. Deliverable 3: A bi-monthly overview report will be presented to the Project Officer and select personnel. Deliverable 4: Per experiment, using raw data, the contractor will provide a summary figure with legend for each experiment initiated. Deliverable 5: Upon completion of work, a final summary report will be submitted to the Project Officer via email. 3. Additional Requirements: 1: The candidate should have a PhD in Pharmaceutical Science and more than seven (7) years' experience in the US in the field of molecular biology performing genetic analysis using the latest microarray technology. 2: The candidate should have a demonstrated scientific publication record in the field of correlating transcript expression with phenotypic expression. 3: The candidate should have developed new software techniques (manual and automated) for use in the diagnosis detection of correlations between transcript changes and cellular phenotypes. 4: The candidate should have a demonstrated record of innovation such as patent applications related to the detection of differentially expressed transcripts. 5: The candidate should have publication record of experience working with viruses and Adeno associated virus gene transfer vectors. 6: The candidate should have demonstrated experience in technical writing as shown by first author publications and successful grant application. (vii) Period of Performance is from 1/2/15 - 9/30/15 Place of Performance National Institutes of Health, NIDCR 10 Center Drive Building 10, Room 1A21 Bethesda, MD 20892 (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, is applicable. The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Contract award shall be made to the responsible Offeror whose offer, in conforming to this RFQ, provides the overall best value to the Government, technical evaluation factors, and cost considered. The Government's objective is to obtain the highest technical quality considered necessary to achieve the project objectives, with a realistic and reasonable cost. Technical evaluation factors are more important than cost. In the event proposals are evaluated as technically equal in quality, price or cost will become a major consideration in selecting the successful Offeror. 1: Technical Capabilities: 1A: Related Experience: Demonstrated understanding of the requirements and capabilities to perform the requirements as outlined in the statement of work. 1B: Educational background: Demonstrated ability to meet the requirements as stated in additional requirements. 2: The offeror will provide the following: 2A: Provide cost estimate, broken down into hourly compensation 2B: Provide most recent resume narrating capabilities to meet the additional requirements as stated 2C: Provide a capability statement stating the relatable experience and education background necessary to complete the tasks as stated under the statement of work. (x) FAR clause 52.212-3, Offeror Representations and Certifications - Commercial Items, is applicable. An offeror shall complete only paragraphs (b) of this provision if the offeror has completed the annual representations and certificates electronically via http://www.acquisition.gov. If an offeror has not completed the annual representations and certifications electronically at the System for Award Management (SAM) website, the offeror shall complete only paragraphs (c) through (p) of this provision. (xi) FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items, applies to this acquisition. Including the following clauses: i. 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving (AUG 2011) ii. 52.225-13, Restrictions on Certain Foreign Purchases iii. 52.244-6, Subcontracts for Commercial Items iv. 52.2232-39, Unenforceability of Unauthorized Obligations v. 52.217-8, Option to extend services The Government may require continued performance of any services within the limits and at the rates specified in the contract. These rates may be adjusted only as a result of revisions to prevailing labor rates provided by the Secretary of Labor. The option provision may be exercised more than once, but the total extension of performance hereunder shall not exceed 6 months. The Contracting Officer may exercise the option by written notice to the Contractor within 30 days (xiii) Additional Contract Requirements: None (xiv) The Defense Priorities and Allocations System (DPAS) and assigned rating are not applicable. (xv) All responses must be received by December 17th, 2014 at 9:00 AM and must reference number HHS-NIH-NHLBI-CSB-DE-2015-039-KEW. Responses may be submitted electronically to Kyle.Wisor@nih.gov or by U.S. mail to the National Heart, Lung, and Blood Institute, Office of Acquisitions, COAC Services Branch, 6701 Rockledge Drive, Suite 6150B, Bethesda, MD 20892-7902, Attention: Kyle Wisor. Phone: 301-402-3670; Fax responses will not be accepted (17) Place of Contract Performance: National Institutes of Health, NIDCR 10 Center Drive Building 10, Room 1A21 (18) Set-aside Status: None
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NIH-NHLBI-CSB-DE-2015-039-KEW/listing.html)
- Place of Performance
- Address: 10 Center Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03591618-W 20141211/141209235025-40259fca7df1c2b6a44c79c4a1c6fa7c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |